Tian Baoguo, deputy director of the Department of Science and Technology for Social Development of the Ministry of Science and Technology of China, said that so far, China has vaccinated about 60,000 subjects and has not received reports of serious adverse reactions, which initially shows good safety.
Liu Jingzhen, Secretary of the Party Committee of Sinopharm Group, said that China Biologics under the group has conducted three-phase trials in 10 countries including the UAE and Bahrain. More than 50,000 people have been inoculated, and the sample size covers the nationalities of 125 countries. They are of different ages and different genders. , Has not received any report of serious adverse reactions.
He went on to point out that China Biotech is ready for large-scale production and can produce more than 1 billion doses next year; Gao Qiang, the general manager of Kexing Zhongwei, said that it will reach 300 million doses next year and 100 million doses by the end of this year.
Tian Baoguo said at the meeting that adverse reactions of any vaccine after research and development or marketing are possible. During the development of the coronavirus vaccine, there have been some adverse reactions. But the reports received were all mild, with only low-grade fever or redness and swelling.
According to comprehensive media reports, the Joint Prevention and Control Mechanism of the State Council of China held a press conference on Tuesday afternoon, inviting many government officials and vaccine research and development units to attend the interview.
China’s current four coronavirus vaccine research and development programs have entered Phase III clinical trials, which is only one step away from the market launch.
China has prepared for large-scale vaccine production
According to the “Beijing Daily” report, the Joint Prevention and Control Mechanism of the State Council of China held a press conference today (20th) to introduce the vaccine.
According to Tian Baoguo, deputy director of the Department of Science and Technology of Social Development, Ministry of Science and Technology, China is currently in a leading position in vaccine research and development, and 13 vaccines have entered the clinical stage. Four vaccines, including inactivated vaccines and adenovirus vector vaccines that have entered Phase III clinical trials.
Moreover, the four vaccines that have entered the phase III clinical trials are generally progressing smoothly. Up to now, a total of about 60,000 subjects have been vaccinated. Furthermore, no reports of serious adverse reactions have been received, initially showing good safety.
Previously, the chairman of Sinopharm Group said that China has already begun to use inactivated vaccines for COVID-19 urgently in China. At present, China National Biotech has prepared for large-scale production and can guarantee sufficient and safe vaccine supplies.
4 vaccines enter Phase III trial
He pointed out that at the beginning of this year, China has deployed inactivated vaccines, recombinant protein vaccines, vector vaccines. Attenuated influenza vector vaccines, and 5 technical routes of nucleic acid vaccines in parallel research and development. Organized 12 superior teams to conduct joint research and strictly follow relevant laws and regulations. Under the premise of ensuring safety, conduct research and development work in a standardized and orderly manner.
Furthermore, he said that China’s vaccine research and development work is generally in a leading position. Every technical route has vaccines that have entered the clinical research stage. Specifically, 13 vaccines have entered clinical trials. Among them, two technical routes of inactivated vaccines and adeno-vector vaccines, a total of 4 vaccines have entered Phase III clinical trials.
The above-mentioned four vaccines are China Biotech II under the Sinopharm Group, one from Kexing Zhongwei. One from Academician Chen Wei of the Chinese People’s Liberation Army.
Yiwu takes the lead in providing vaccines
Although the Phase III clinical trials have not yet been completed, Yiwu City. This is known as a small commodity distribution centre in eastern China, has begun to provide vaccines to the public. Furthermore, BBC China correspondent Robin saw hundreds of people waiting outside a community hospital in Yiwu. Moreover, they do not need to make an appointment. They only need to pay 400 yuan (about 248 Ringgit) on the spot to get the vaccination.
This small city in Zhejiang Province is one of the first regions in China and the world to provide vaccines to the public. In addition, there are a large number of local people doing business all over the world.
More information about:
- Obesity has a higher death rate in coronavirus
- Face masks become mandatory in Rome as coronavirus cases spike
- Coronavirus in University of Newcastle
- China tests vaccine in 60,000 people without adverse effects, official says
- Some 60,000 injected with China’s COVID-19 vaccines with no ill effect